Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer.
Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.
Repetto
L
L
Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Miglietta
L
L
Gardin
G
G
Naso
C
C
Giudici
S
S
Merlini
L
L
Queirolo
P
P
Campora
E
E
Pronzato
P
P
Rosso
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage
D016685:Mitomycin; D008942:Mitoxantrone